Oncotelic Therapeutics, Inc.

What they do

Oncotelic develops antisense and small molecule drugs for cancer, with OT-101 as its lead product candidate and additional compounds OXi4503 and CA4P under evaluation. Since April 2022 it has conducted the vast majority of OT-101 development through GMP Biotechnology Limited, a joint venture with Dragon Overseas Capital, to which it contributed worldwide OT-101 license rights for a 45% interest while Dragon agreed to provide approximately $27.6 million in R&D funding for 55%. Other subsidiaries include PointR Data (AI for clinical trials), Pet2DAO (animal health), and EdgePoint AI. It also acquired apomorphine for Parkinson's disease, erectile dysfunction and female sexual dysfunction.

Revenue drivers

• Joint venture equity interest (GMP Bio) — The company's principal asset is its 45% interest in GMP Bio, accounted for under the fair value option, so changes in fair value flow through income rather than operating revenue.
• Product sales / licensing — The company is development stage with no approved or commercially marketed products; reported annual revenue was $70,000 in 2023, and quarterly revenue was $250,000 for the period ended 2026-06-30.
• OT-101 pipeline rights — OT-101 U.S. and rest-of-world license rights were contributed to the JV; FDA Rare Pediatric Designations were granted for pediatric DIPG (OT-101), pediatric melanoma (CAP4) and AML (Oxi4503).
• Strategic alliances and licensing — The company states it explores forming strategic alliances and/or licensing its product portfolio to create shareholder value, with the JV IPO contemplated as a potential liquidity event.

Recent performance

Fiscal 2025 net income was $249.3 million, or $0.59 diluted EPS, driven by a recorded change in the value of its GMP Bio interest of approximately $365.4 million, compared with a $4.5 million net loss in 2024. Operating cash flow remained negative at -$1.4 million in 2025 and -$740,277 in 2024. As of 2026-06-30, total assets were $394.8 million against total liabilities of $131.3 million and shareholder equity of $264.6 million. Cash and equivalents were only $409,000 as of 2025-09-30, and quarterly revenue for 2026-06-30 was $250,000. The 2025 result follows recurring losses, including -$9.4 million in 2021, -$7.9 million in 2023 and -$4.5 million in 2024.

Strategy

The company's stated direction is to develop OT-101 and additional compounds through the GMP Bio JV, targeting TGF-beta overexpression in cancer and expanding toward Duchenne Muscular Dystrophy and other diseases. It aims to leverage FDA Rare Pediatric Designations to reduce clinical development cost and time, obtain regulatory exclusivity, and pursue voucher programs worth potentially several million dollars. Management says GMP Bio is progressing strategic and operational plans, including securing third-party financing and a possible initial public offering in Hong Kong during 2026, and has stated that the JV obtained a preliminary third-party valuation of approximately $2.3 billion for its pipeline, implying roughly $1 billion for the company's 45% interest. The company also describes exploring alliances and licensing of its portfolio.

Risks

• Principal asset is a minority JV interest — The company's principal asset is a minority interest in GMP Bio, and its financial statements do not include a balance sheet or statement of operations for the JV, making the underlying value difficult for investors to assess.
• JV is pre-revenue and hard to value — The JV is a development-stage venture with no approved or commercially marketed products and no established public trading market for its interests, so changes in development results or valuation assumptions could produce material impairment charges or volatility.
• Thin cash and recurring operating losses — Cash and equivalents were only $409,000 as of 2025-09-30 and operating cash flow was -$1.4 million in 2025, so the company depends on future debt or equity financing to meet operating costs.
• Uncertain JV IPO and financing — The contemplated Hong Kong IPO and third-party financing for GMP Bio are described as not assured, and the company states it cannot provide assurance the IPO can be completed or would be successful.

Outlook

Management points to GMP Bio's strategic and operational plans, including efforts to secure third-party financing and a possible Hong Kong initial public offering during 2026. It says the JV completed a Phase 1 trial of OT-101 in combination with IL-2 and describes the pipeline valuation as non-binding and not determinative of fair value under U.S. GAAP. The company says it will adjust the fair value of its JV interest at reporting periods and when key value inflection points are met. It also states it may need future debt or equity financing to meet operating costs.